CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 21 enrolled
Drug / intervention
Dasatinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00429949
NCT00429949Phase 2Completed
CompareCT.gov

A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma

Washington University School of Medicine·interventional·Posted Feb 1, 2007·Updated Aug 29, 2014

In Brief

A Phase 2 clinical trial evaluating Dasatinib for Relapsed, Refractory or Plateau Phase Multiple Myeloma. Completed, enrolled 21 participants across 1 site.

Detailed Summary

To evaluate the response rate (Complete Response \[CR\] and Partial Response \[PR\]) to dasatinib in patients with relapsed, refractory or plateau phase multiple myeloma whose serum paraprotein levels are \>0.5g/dL or urine paraprotein levels are \>1.0g/24 hours.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsed, Refractory or Plateau Phase Multiple Myeloma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 1, 2007
Enrollment StartJan 1, 2007
Primary CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 19.4 years ago

Interventions

Dasatinibdrug